Cytokine News and Research

RSS

Nasal viruses may drive allergic rhinitis, and ribavirin shows early promise as a targeted spray treatment

Nasal commensal viruses may worsen allergic rhinitis by activating type I IFN-linked neutrophils and NET formation. Ribavirin reduced nasal viral abundance and improved symptoms in mice and in a small phase 2 trial.

28 Jun 2026

New review highlights TREM-1 receptor as target for inflammatory diseases

A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.

25 Jun 2026

New biomarkers identify trauma patients at risk for chronic critical illness

New research, published in The Journal of Immunology, identified biomarkers of a distinct immune profile that could be used to identify patients at risk for chronic critical illness (CCI) upon admittance to the intensive-care unit (ICU) after traumatic injury.

25 Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

Immunotherapy helps bridge cancer patients to curative liver transplantation

Liver transplantation remains one of the most powerful curative options for hepatocellular carcinoma (HCC) because it removes both the tumor and the diseased liver.

22 Jun 2026

Repurposed cancer therapy enables successful kidney transplantation

A pioneering clinical trial has successfully enabled three patients with end-stage kidney disease to receive previously improbable kidney transplants.

4 Jun 2026

Novel CAR T treatment makes previously impossible kidney transplants possible

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants.

3 Jun 2026

CAR-T cell therapy shows promise for treating rheumatoid arthritis

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

3 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

Silica nanoparticles dampen early allergy signals in mouse mast cells

This in vitro study found that negatively charged SiO2 nanoparticles suppressed antigen-induced degranulation and activation-marker changes in IgE-sensitized mouse bone marrow-derived mast cells. By contrast, mTiO2 nanoparticles showed cytotoxic and pro-inflammatory effects, including enhanced DNP-induced IL-6 release, suggesting nanoparticle composition can shape early allergic immune responses.

24 May 2026

RNA modifications shape gut immunity and intestinal macrophage function

A new perspective on gut immunity is highlighting the powerful role of RNA modifications in shaping how the body maintains balance in the digestive system.

24 May 2026

Pim1 identified as promising therapeutic target for inflammatory arthritis treatment

The research team led by Professor Zhongyu Xie from Sun Yat-sen University revealed a new mechanism by which Pim1 regulated Th17 cell differentiation through mitochondrial metabolism.

22 May 2026

Graph neural networks accelerate drug discovery for complex bone diseases

Announcing a new publication for Acta Materia Medica journal. Traditional Chinese medicine has shown therapeutic potential in treating osteoarthritis (OA) by regulating inflammation and maintaining cartilage homeostasis.

22 May 2026

Could blocking inflammation help treat difficult-to-treat depression?

A small proof-of-concept RCT found that tocilizumab, an IL-6 receptor blocker, showed a non-significant but clinically suggestive pattern of improvement in difficult-to-treat depression linked to low-grade inflammation. The study found that baseline hs-CRP, rather than IL-6, may help identify patients most likely to respond, supporting larger trials of immune-targeted depression care.

22 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Anti-inflammatory drug tocilizumab shows promise for difficult-to-treat depression

Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key finding from a University of Bristol-led pilot randomised controlled clinical trial, published in JAMA Psychiatry today [20 May].

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Precision calcium signaling control may improve future CAR-T therapies

Calcium is widely known for its role in maintaining strong bones and teeth, but it is also one of the body's most important cellular messengers.

19 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026